|
17 Dec 2022
|
Gufic BioSciences
|
KamayaKya Wealth
|
341.50
|
254.40
|
216.15
(57.99%)
|
Target met |
Buy
|
|
|
Going forward, we estimate a 20% CAGR till FY24 (based on non COVID-19 products), driven by doubling of capacities in the lyophilisation segment, increase in market share of niche products and new product launches coupled with geographical expansion.
|